Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma AB, a Swedish commercial-stage biopharmaceutical company specializing in IgG-cleaving immunomodulatory therapies for transplantation, gene therapy and autoimmune diseases, is expanding its reach with products such as imlifidase and its next-generation candidate HNSA-5487. Listed on Nasdaq Stockholm and active in Europe and the U.S., the company is positioning its proprietary enzyme platform to address high unmet medical needs in complex immune-mediated conditions.
The company announced that CEO Renée Aguiar-Lucander will take part in a fireside chat at the DNB Carnegie Healthcare Conference 2026 in Stockholm on 12 March, with VP Global Corporate Affairs Kerstin Falck also attending. Participation in this high-profile healthcare investor event underscores Hansa Biopharma’s efforts to engage the financial community, raise its visibility among investors and stakeholders, and highlight the strategic progress of its immunology-focused pipeline and commercial activities.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK30.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing novel immunomodulatory therapies for acute and complex immune disorders. Built around its proprietary IgG-cleaving enzyme technology platform, the company targets serious unmet medical needs in transplantation, gene therapy and autoimmune diseases across Europe and the U.S.
Its portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy enabling kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule being developed for Guillain-Barré Syndrome. Headquartered in Lund, Sweden, Hansa Biopharma is listed on Nasdaq Stockholm under the ticker HNSA and maintains a growing international operational footprint.
Average Trading Volume: 515,664
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK2.99B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.